High-performance liquid chromatographic determination of Levetiracetam in human plasma: comparison of different sample clean-up procedures

An accurate and precise high-performance liquid chromatographic method using diode array detection for the determination of the novel antiepileptic, Levetiracetam, has been developed. Three clean-up procedures for the analysis of Levetiracetam in human plasma were implemented and evaluated, namely solid-phase extraction, deproteinization by addition of organic solvents and formation of insoluble salts. Adenosine was used as the internal standard for all three sample pretreatment procedures. Among the several cartridges used for solid-phase extraction, the hydrophilic-lypophilic balance (Oasis) HLB) phase provides the best extraction yield of Levetiracetam, together with high precision. With the two other clean-up procedures involving plasma deproteinization by addition of methanol or zinc sulphate, lower sensitivity and precision of the assays were obtained. However, they are cheaper and faster when compared with the solid-phase extraction procedure.     

An in vitro controlled release study of valproic acid encapsulated in a titania ceramic matrix

Despite the therapeutic efficacy of valproic acid towards numerous diseases, its poor bioavailability and systemic side effects pose significant barriers to long term treatment. In order to take advantage of controlled release implants of valproic acid, the drug was encapsulated into titania ceramic matrices via a sol-gel process. The integrity and structure of valproic acid-containing matrices were characterized through the use of FESEM, TEM, and BET analyses. In vitro controlled release studies and kinetic analyses were performed under ambient conditions (25 °C, atmospheric pressure) and controlled release behaviors were studied using a GC-MS method. Results showed first order dependence in the rate of valproic acid release as a function of drug concentrations in the titania ceramic device. A marked dependence on the surface area and pore size distribution with drug loading was also observed. This research opens new possibilities for the design of novel time-delayed controlled release systems for valproic acid encapsulates.     

Quantitation of oxcarbazepine and its metabolites in human plasma by micellar electrokinetic chromatography

A reliable micellar electrokinetic chromatographic method for the determination of oxcarbazepine and its two main metabolites, 10-hydroxycarbamazepine and 10,11-trans-dihydroxy-10,11-dihydroxycarbamazepine, in human plasma was developed. The separation and determination of the analytes was achieved using a system consisting of 60 mM SDS in phosphate buffer (30 mM, pH 8.0), to which 20% (v/v) methanol was added. Separation was carried out in an uncoated fused-silica capillary with a separation voltage of 25 kV and currents typically less than 40 microA. Spectrophotometric detection was at 205 nm. Isolation of oxcarbazepine and its metabolites from plasma was accomplished by a solid-phase extraction procedure. The mean extraction yield of the analytes from plasma was higher than 94%. The linear correlation coefficients were better than 0.994 for all analytes. The limit of detection was 0.05 microg/mL, the limit of quantitation 0.15 microg/mL. The repeatability for the spiked blank plasma samples was lower than 1.9% and the intermediate precision lower than 2.1%, both expressed as RSD%. The results obtained analysing real plasma samples from epileptic patients under therapy with Tolep were satisfactory in terms of precision, accuracy and detectability.     

Development and evaluation of a simple and easy high-performance liquid chromatography–ultraviolet system simultaneously suitable for determination of 24 anti-epileptic drugs in plasma

We aim to establish a simple and easy high-performance liquid chromatography system coupled with an ultraviolet detector suitable for simultaneous determination of 24 antiepileptic drugs in human plasma. Optimized chromatographic separation was performed on a ZORBAX Eclipse Plus-C18 (4.6 × 150 mm², 3.5 μm) column with acetonitrile and 5 mM potassium dihydrogen phosphate water solution as mobile phase. Note that, 24 antiepileptic drugs were divided into three groups and eluted with different gradient procedures, respectively. The column temperature was maintained at 35°C and the detection wavelength was set at 210 nm. Plasma was processed with ethyl acetate or acetonitrile. The calibration curves of 24 antiepileptic drugs demonstrated good linearity within the test range (r > 0.996). The intra- and inter-batch precision and accuracy were all less than 15%, while extraction recoveries were in the range of 74.57–90.89% with the relative standard deviation values less than 15%. The validated methods have been successfully applied to determination of some antiepileptic drugs in rat or patient plasma. Those results indicated that the developed methods were simple and easy, and could be suitable for the determination of 24 antiepileptic drugs in plasma just by changing the gradient elution procedures of mobile phase.     

On the origin of the lack of anticonvulsant activity of some valpromide derivatives

Two closely related N-substituted valpromide derivatives: N-valproyl glycinamide and N-valproyl glycine are comparatively analyzed, the first of which is antiepileptic active whereas the second is not. The study is based on a conformational analysis using an AM1 Hamiltonian that not only search for the lower energy structures of each derivative but also for the energy involved in their mutual interconversion. Open structures have been compared with cyclic ones, the latter including those stabilized by either inter or intra molecular hydrogen bonds (dimers and monomers, respectively). H-bond formation has been also evaluated by means of ab initio G94(6–31+G(d,p)) calculations for a smaller system (N-formylglycine/glycinamide) modeling both vacuum and solvent conditions. The conformational and electronic characteristics of the open and cyclic monomers, as well as of the dimer N-valproyl glycinamide and N-valproyl glycine structures are discussed. On the basis of the results of their comparative analysis, we have redefined the pharmacophore previously proposed for N-substituted valpromides [Tasso, Bruno-Blanch, Estiu, Int. J. Quant. Chem. 65 (6), 1107 (1997)], relaxing some of the associated requirements. The corrected model requires one carbon atom or any bioisosteric substituent in an anticlinal conformation relative to the aminic nitrogen of the amide moiety, in addition to one hydrogen atom that should be antiperiplanar to the carbonyl oxygen. This model offers an explanation to the different response of N-valproyl glycinamide and N-valproyl glycine against convulsion, which is based on conformational restrictions. © 1998 John Wiley & Sons, Inc. Int J Quant Chem 70: 1127–1136, 1998     

The use of separation techniques in the analysis of some antiepileptic drugs: A critical review

In the last few decades, many new antiepileptic drugs came out to medicine world, and their use was expanded over a wide range of cases. Analysts from all over the world developed many different separation methods for the determination of these drugs in a quantitative way either in pharmaceutical dosage forms or in biological fluids. In this review article, a summation of previously published separation methods including high-performance thin-layer chromatography, high-performance liquid chromatography, gas chromatography, and electrophoresis used for the determination of eslicarbazepine acetate, levetiracetam, lacosamide, oxcarbazepine, pregabalin, and retigabine are presented. These six drugs are the most commonly used drugs for the treatment of patients diagnosed with partial onset seizures. This article can help researchers and analysts to build upon this knowledge and add further methods of analysis in the future.     

A simple and easy non-derivatization gas chromatography-mass spectrometry method for simultaneous quantification of valproic acid,gabapentin, pregabalin,and vigabatrin in human plasma

Immunoassays are currently not available in commercial kits for the quantification of valproic acid, vigabatrin, pregabalin, and gabapentin, which also cannot suffer the limitations of interferences of substances with similar structures. Chromatography is a good alternative to immunoassay. In this study, a simple and robust non-derivatization gas chromatography-mass spectrometry method for simultaneous determination of the above four drugs in human plasma was developed and validated for therapeutic drug monitoring purposes. This method employed benzoic acid as the internal standard with hydrochloric acid for plasma acidification and ACN for precipitate protein. The supernatant was directly injected into gas chromatography-mass spectrometry for analysis. Good linearity was obtained with linear correlation coefficients of the four analytes of 0.9988–0.9996. Extraction recoveries of valproic acid, vigabatrin, pregabalin, and gabapentin were respectively in the ranges of 91.3%–94.5%, 90.0%–90.9%, 90.0%–92.1%, and 88.0%–92.2% with the relative standard deviation values less than 12.6%. Intra- and inter-batch precision and accuracy, and stability assays were all acceptable. Taken together, the novel method developed in this study provided easy plasma pretreatment, good extraction yield, and high chromatographic resolution, which has been successfully validated through the quantification of valproic acid in the plasma of 46 patients with epilepsy.     

Highly sensitive UHPLC–DAD method for simultaneous determination of two synergistically acting antiepileptic drugs; levetiracetam and lacosamide: Application to pharmaceutical tablets and human urine

A simple and highly sensitive ultra‐high‐performance liquid chromatographic–diode array (UHPLC‐DAD) detection method was developed and validated for the simultaneous estimation of levetiracetam (LEV) and lacosamide (LAC). It was clinically proven that the combination of LEV and LAC exhibits a synergistic effect against refractory seizures in mice, which was the motivation for the analysis of this binary mixture both in bulk and in human urine samples. The binary mixture was resolved on a Hypersil BDS C₁₈ analytical column, utilizing a mobile phase of 0.050 mol L^?1 phosphate buffer (pH 5.60), methanol and acetonitrile in the ratio (80:10:10 v/v/v) using catechol as an internal standard. The mobile phase was pumped at a flow rate of 1.2 mL min^?1 with diode array detection at 205 nm for both drugs and 270 nm for IS. Calibration curves were linear with correlation coefficient >0.9990 over the studied concentration range of 0.1–70.0 μg mL^?1 for both drugs. The developed method was reproducible with low relative standard deviation values for intra‐ and inter‐day precision (<2.0%). Both drugs were determined in bulk, pharmaceutical formulations and human urine samples without any interference from complex matrices.     

Spectroscopy properties of the amide group in valpromide and some derivatives with antiepileptic activity

Infrared spectra at 300 and 77 K and Raman spectra at 300 K of the valpromide (Vpd), N‐substituted derivatives, N‐ethylvalpromide (Etvpd), N‐isopropylvalpromide (Ipvpd) and the N,N‐disubstituted derivative, N,N‐dimethylvalpromide (Dmvpd) with antiepileptic activity, have been measured and analyzed with results derived from computational chemistry calculation. In agreement with theoretical predictions, experimental data indicate that while in Etvpd, Dmvpd and Ipvpd there are four different conformational co‐existing components (Etvpd: TTCG⁺, TCCG⁻, TTTC, G⁺G⁺C G⁺; Dmvpd: TTCC, G⁻TTA⁺, G⁺A⁻TC, G⁺A⁻C A⁺; Ipvpd: TTCT, TCCT, TCCC, G⁻ TTT) in the Vpd there are only three distinct stable conformations of C₁ symmetry group: TTC, TCT, G⁺G⁺T. Based on the accuracy of the B3LYP calculation, with the 6‐31 + G** basis set estimated by comparison between the predicted values of the vibrational modes and the available experimental data, we performed a structural and vibrational study of the amide group in the Vpd and their derivatives. We found that small nonplanarity deviations of C(O)N backbone induce significant changes on the structural and spectroscopic properties. These are not compatible with the decreasing of the resonance effect as it is produced when the twisting around the C(O) N increases. From the Natural Bond Orbital (NBO) analysis the existence of stabilizing electrostatic interactions of type C H···O/N and C H···H N/C, which induce significant structural changes and a complex electronic redistribution of charge on the π‐system in those structures becomes evident. We view this as a consequence of the filled electron density change Lewis‐type NBOs type lp_{O1, 2}, lp_N1, σ_{(C H)N acyl} and empty non‐Lewis NBOs type σ*_{(C H)N acyl}, σ*_{N H}. Copyright © 2009 John Wiley & Sons, Ltd.     

Simultaneous determination of four antiepileptic drugs in human plasma samples using an ultra‐high‐performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring

Therapeutic drug monitoring of antiepileptic drugs is widely practiced to achieve optimal efficacy and avoid adverse side effects. We describe an ultra‐high‐performance liquid chromatography tandem mass spectrometry (UHPLC/MS/MS) method developed for the monitoring of four frequently prescribed antiepileptic drugs – lamotrigine, levetiracetam, oxcarbazepine and topiramate. The main pharmacologically active metabolite of oxcarbazepine (mono‐hydroxy‐derivative metabolite, MHD) was also quantified. After addition of internal standards and a simple stage of protein precipitation, plasmatic samples were analyzed on a C₁₈ column. All antiepileptic drugs were separated and quantified in 6 min, without interference. A good linearity was observed all over the calibration range (r² > 0.99), up to 20 μg/mL (40 μg/mL for MHD). The limit of quantification was 0.20 μg/mL (0.40 μg/mL for MHD) with precision and accuracy ranging from 1.0 to 2.1% and from 96.7 to 110.8%, respectively. Intra‐ and inter‐day precision and accuracy values were within 15%. No significant matrix effect was observed for all analytes. Clinical application was successfully evaluated in 259 samples from patients treated for epilepsy or bipolar disorders. In conclusion, a rapid, specific and sensitive UHPLC/MS/MS method was developed and validated for simultaneous quantification of antiepileptic drugs, suitable for therapeutic drug monitoring in neurology and psychiatry.